Haisco Pharmaceutical Group has received acceptance for its clinical trial application for HSK51155 tablets from China's National Medical Products Administration. This drug is an orally administered small molecule non-opioid innovative analgesic, developed independently by the company. It aims to provide pain relief while minimizing adverse effects and avoiding addiction risks. AI
IMPACT Potential for new pain management options with reduced side effects and addiction risk.
RANK_REASON Clinical trial application acceptance for a novel drug candidate. [lever_c_demoted from research: ic=1 ai=0.4]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →